Given the detrimental effects of IL-6R blockade on TGFβ-specific immunity in pancreatic cancer observed in our preclinical studies and the sole distinction between patients in the CheckPAC and TRIPLE-R trials being tocilizumab treatment, we compared patients across the two studies to elucidate any impact of IL-6R blockade. The gene discussed is TGFB1; the disease is familial pancreatic carcinoma.